 | • レポートコード：D0GIR-11213 • 出版社/出版日：GlobalInfoResearch / 2020年9月23日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、HIV治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。HIV治療薬の種類別市場規模（非ヌクレオシド系逆転写酵素阻害剤（NNRTI）、インテグラーゼ阻害剤、HIV併用薬、その他）、用途別市場規模（病院薬局、小売薬局、オンライン薬局、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：ViiV Healthcare、Genentech, Inc.、Bristol-Myers Squibb Company、Gilead Sciences, Inc、Mylan Pharmaceuticals Inc.、Merck Sharp & Dohme Corp、Theratechnologies Inc.、Janssen Pharmaceuticals, Inc.、AbbVie Inc. ・地域別グローバル市場分析 2015年-2020年 ・HIV治療薬の北米市場（アメリカ、カナダ、メキシコ） ・HIV治療薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・HIV治療薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・HIV治療薬の南米市場（ブラジル、アルゼンチン） ・HIV治療薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：非ヌクレオシド系逆転写酵素阻害剤（NNRTI）、インテグラーゼ阻害剤、HIV併用薬、その他 ・用途別分析：病院薬局、小売薬局、オンライン薬局、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The Drugs for HIV market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Drugs for HIV sales will be xx in 2020 from Drugs for HIV million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Drugs for HIV market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Drugs for HIV industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Drugs for HIV and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Drugs for HIV market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Drugs for HIV market has been segmented into
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Integrase Inhibitors
Combination HIV Medicines
Others
By Application, Drugs for HIV has been segmented into:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Drugs for HIV market presented in the report. This section sheds light on the sales growth of different regional and country-level Drugs for HIV markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Drugs for HIV market.
The report offers in-depth assessment of the growth and other aspects of the Drugs for HIV market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Drugs for HIV Market Share Analysis
Drugs for HIV competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Drugs for HIV sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Drugs for HIV sales, revenue and market share for each player covered in this report.
The major players covered in Drugs for HIV are:
ViiV Healthcare
Genentech, Inc.
Bristol-Myers Squibb Company
Gilead Sciences, Inc
Mylan Pharmaceuticals Inc.
Merck Sharp & Dohme Corp
Theratechnologies Inc.
Janssen Pharmaceuticals, Inc.
AbbVie Inc.
Among other players domestic and global, Drugs for HIV market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Drugs for HIV product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Drugs for HIV, with price, sales, revenue and global market share of Drugs for HIV in 2018 and 2019.
Chapter 3, the Drugs for HIV competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Drugs for HIV breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Drugs for HIV market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Drugs for HIV sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Drugs for HIV Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Drugs for HIV Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.2.3 Integrase Inhibitors
1.2.4 Combination HIV Medicines
1.2.5 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Drugs for HIV Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Overview of Global Drugs for HIV Market
1.4.1 Global Drugs for HIV Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
1.6 COVID-19 Outbreak: Drugs for HIV Industry Impact
1.6.1 COVID-19 Potential Implications for the Drugs for HIV
1.6.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Drugs for HIV
1.6.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.6.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.6.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.6.2 Opportunity Analysis in Covid-19 Crisis
1.6.3 Market Risk and Restraints
1.6.4 Market Driving Force
2 Manufacturers Profiles
2.1 ViiV Healthcare
2.1.1 ViiV Healthcare Details
2.1.2 ViiV Healthcare Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 ViiV Healthcare SWOT Analysis
2.1.4 ViiV Healthcare Product and Services
2.1.5 ViiV Healthcare Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Genentech, Inc.
2.2.1 Genentech, Inc. Details
2.2.2 Genentech, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Genentech, Inc. SWOT Analysis
2.2.4 Genentech, Inc. Product and Services
2.2.5 Genentech, Inc. Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Bristol-Myers Squibb Company
2.3.1 Bristol-Myers Squibb Company Details
2.3.2 Bristol-Myers Squibb Company Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Bristol-Myers Squibb Company SWOT Analysis
2.3.4 Bristol-Myers Squibb Company Product and Services
2.3.5 Bristol-Myers Squibb Company Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Gilead Sciences, Inc
2.4.1 Gilead Sciences, Inc Details
2.4.2 Gilead Sciences, Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Gilead Sciences, Inc SWOT Analysis
2.4.4 Gilead Sciences, Inc Product and Services
2.4.5 Gilead Sciences, Inc Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Mylan Pharmaceuticals Inc.
2.5.1 Mylan Pharmaceuticals Inc. Details
2.5.2 Mylan Pharmaceuticals Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Mylan Pharmaceuticals Inc. SWOT Analysis
2.5.4 Mylan Pharmaceuticals Inc. Product and Services
2.5.5 Mylan Pharmaceuticals Inc. Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Merck Sharp & Dohme Corp
2.6.1 Merck Sharp & Dohme Corp Details
2.6.2 Merck Sharp & Dohme Corp Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Merck Sharp & Dohme Corp SWOT Analysis
2.6.4 Merck Sharp & Dohme Corp Product and Services
2.6.5 Merck Sharp & Dohme Corp Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Theratechnologies Inc.
2.7.1 Theratechnologies Inc. Details
2.7.2 Theratechnologies Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Theratechnologies Inc. SWOT Analysis
2.7.4 Theratechnologies Inc. Product and Services
2.7.5 Theratechnologies Inc. Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 Janssen Pharmaceuticals, Inc.
2.8.1 Janssen Pharmaceuticals, Inc. Details
2.8.2 Janssen Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Janssen Pharmaceuticals, Inc. SWOT Analysis
2.8.4 Janssen Pharmaceuticals, Inc. Product and Services
2.8.5 Janssen Pharmaceuticals, Inc. Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.9 AbbVie Inc.
2.9.1 AbbVie Inc. Details
2.9.2 AbbVie Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 AbbVie Inc. SWOT Analysis
2.9.4 AbbVie Inc. Product and Services
2.9.5 AbbVie Inc. Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Drugs for HIV Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Drugs for HIV Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Drugs for HIV Manufacturer Market Share in 2019
3.3.2 Top 6 Drugs for HIV Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Drugs for HIV Sales, Revenue and Market Share by Regions
4.1.1 Global Drugs for HIV Sales and Market Share by Regions (2015-2020)
4.1.2 Global Drugs for HIV Revenue and Market Share by Regions (2015-2020)
4.2 North America Drugs for HIV Sales and Growth Rate (2015-2020)
4.3 Europe Drugs for HIV Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Drugs for HIV Sales and Growth Rate (2015-2020)
4.5 South America Drugs for HIV Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Drugs for HIV Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Drugs for HIV Sales, Revenue and Market Share by Country
5.1.1 North America Drugs for HIV Sales and Market Share by Country (2015-2020)
5.1.2 North America Drugs for HIV Revenue and Market Share by Country (2015-2020)
5.2 United States Drugs for HIV Sales and Growth Rate (2015-2020)
5.3 Canada Drugs for HIV Sales and Growth Rate (2015-2020)
5.4 Mexico Drugs for HIV Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Drugs for HIV Sales, Revenue and Market Share by Country
6.1.1 Europe Drugs for HIV Sales and Market Share by Country (2015-2020)
6.1.2 Europe Drugs for HIV Revenue and Market Share by Country (2015-2020)
6.2 Germany Drugs for HIV Sales and Growth Rate (2015-2020)
6.3 UK Drugs for HIV Sales and Growth Rate (2015-2020)
6.4 France Drugs for HIV Sales and Growth Rate (2015-2020)
6.5 Russia Drugs for HIV Sales and Growth Rate (2015-2020)
6.6 Italy Drugs for HIV Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Drugs for HIV Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Drugs for HIV Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Drugs for HIV Revenue and Market Share by Regions (2015-2020)
7.2 China Drugs for HIV Sales and Growth Rate (2015-2020)
7.3 Japan Drugs for HIV Sales and Growth Rate (2015-2020)
7.4 Korea Drugs for HIV Sales and Growth Rate (2015-2020)
7.5 India Drugs for HIV Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Drugs for HIV Sales and Growth Rate (2015-2020)
7.7 Australia Drugs for HIV Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Drugs for HIV Sales, Revenue and Market Share by Country
8.1.1 South America Drugs for HIV Sales and Market Share by Country (2015-2020)
8.1.2 South America Drugs for HIV Revenue and Market Share by Country (2015-2020)
8.2 Brazil Drugs for HIV Sales and Growth Rate (2015-2020)
8.3 Argentina Drugs for HIV Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Drugs for HIV Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Drugs for HIV Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Drugs for HIV Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Drugs for HIV Sales and Growth Rate (2015-2020)
9.3 Turkey Drugs for HIV Sales and Growth Rate (2015-2020)
9.4 Egypt Drugs for HIV Sales and Growth Rate (2015-2020)
9.5 South Africa Drugs for HIV Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Drugs for HIV Sales and Market Share by Type (2015-2020)
10.2 Global Drugs for HIV Revenue and Market Share by Type (2015-2020)
10.3 Global Drugs for HIV Price by Type (2015-2020)
11 Global Drugs for HIV Market Segment by Application
11.1 Global Drugs for HIV Sales Market Share by Application (2015-2020)
11.2 Global Drugs for HIV Revenue Market Share by Application (2015-2020)
11.3 Global Drugs for HIV Price by Application (2015-2020)
12 Market Forecast
12.1 Global Drugs for HIV Sales, Revenue and Growth Rate (2021-2025)
12.2 Drugs for HIV Market Forecast by Regions (2021-2025)
12.2.1 North America Drugs for HIV Market Forecast (2021-2025)
12.2.2 Europe Drugs for HIV Market Forecast (2021-2025)
12.2.3 Asia-Pacific Drugs for HIV Market Forecast (2021-2025)
12.2.4 South America Drugs for HIV Market Forecast (2021-2025)
12.2.5 Middle East & Africa Drugs for HIV Market Forecast (2021-2025)
12.3 Drugs for HIV Market Forecast by Type (2021-2025)
12.3.1 Global Drugs for HIV Sales Forecast by Type (2021-2025)
12.3.2 Global Drugs for HIV Market Share Forecast by Type (2021-2025)
12.4 Drugs for HIV Market Forecast by Application (2021-2025)
12.4.1 Global Drugs for HIV Sales Forecast by Application (2021-2025)
12.4.2 Global Drugs for HIV Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Drugs for HIV Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Drugs for HIV by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Drugs for HIV Market Size and Growth Estimation in Various Scenarios in 2020
Table 4. Global Drugs for HIV Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 5. Market Opportunities in Next Few Years
Table 6. Market Risks Analysis
Table 7. Market Drivers
Table 8. ViiV Healthcare Basic Information, Manufacturing Base and Competitors
Table 9. ViiV Healthcare Drugs for HIV Major Business
Table 10. ViiV Healthcare Drugs for HIV Total Revenue (USD Million) (2018-2019)
Table 11. ViiV Healthcare SWOT Analysis
Table 12. ViiV Healthcare Drugs for HIV Product and Services
Table 13. ViiV Healthcare Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 14. Genentech, Inc. Basic Information, Manufacturing Base and Competitors
Table 15. Genentech, Inc. Drugs for HIV Major Business
Table 16. Genentech, Inc. Drugs for HIV Total Revenue (USD Million) (2018-2019)
Table 17. Genentech, Inc. SWOT Analysis
Table 18. Genentech, Inc. Drugs for HIV Product and Services
Table 19. Genentech, Inc. Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 20. Bristol-Myers Squibb Company Basic Information, Manufacturing Base and Competitors
Table 21. Bristol-Myers Squibb Company Drugs for HIV Major Business
Table 22. Bristol-Myers Squibb Company Drugs for HIV Total Revenue (USD Million) (2018-2019)
Table 23. Bristol-Myers Squibb Company SWOT Analysis
Table 24. Bristol-Myers Squibb Company Drugs for HIV Product and Services
Table 25. Bristol-Myers Squibb Company Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 26. Gilead Sciences, Inc Basic Information, Manufacturing Base and Competitors
Table 27. Gilead Sciences, Inc Drugs for HIV Major Business
Table 28. Gilead Sciences, Inc Drugs for HIV Total Revenue (USD Million) (2018-2019)
Table 29. Gilead Sciences, Inc SWOT Analysis
Table 30. Gilead Sciences, Inc Drugs for HIV Product and Services
Table 31. Gilead Sciences, Inc Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 32. Mylan Pharmaceuticals Inc. Basic Information, Manufacturing Base and Competitors
Table 33. Mylan Pharmaceuticals Inc. Drugs for HIV Major Business
Table 34. Mylan Pharmaceuticals Inc. Drugs for HIV Total Revenue (USD Million) (2018-2019)
Table 35. Mylan Pharmaceuticals Inc. SWOT Analysis
Table 36. Mylan Pharmaceuticals Inc. Drugs for HIV Product and Services
Table 37. Mylan Pharmaceuticals Inc. Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 38. Merck Sharp & Dohme Corp Basic Information, Manufacturing Base and Competitors
Table 39. Merck Sharp & Dohme Corp Drugs for HIV Major Business
Table 40. Merck Sharp & Dohme Corp Drugs for HIV Total Revenue (USD Million) (2018-2019)
Table 41. Merck Sharp & Dohme Corp SWOT Analysis
Table 42. Merck Sharp & Dohme Corp Drugs for HIV Product and Services
Table 43. Merck Sharp & Dohme Corp Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 44. Theratechnologies Inc. Basic Information, Manufacturing Base and Competitors
Table 45. Theratechnologies Inc. Drugs for HIV Major Business
Table 46. Theratechnologies Inc. Drugs for HIV Total Revenue (USD Million) (2018-2019)
Table 47. Theratechnologies Inc. SWOT Analysis
Table 48. Theratechnologies Inc. Drugs for HIV Product and Services
Table 49. Theratechnologies Inc. Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 50. Janssen Pharmaceuticals, Inc. Basic Information, Manufacturing Base and Competitors
Table 51. Janssen Pharmaceuticals, Inc. Drugs for HIV Major Business
Table 52. Janssen Pharmaceuticals, Inc. Drugs for HIV Total Revenue (USD Million) (2018-2019)
Table 53. Janssen Pharmaceuticals, Inc. SWOT Analysis
Table 54. Janssen Pharmaceuticals, Inc. Drugs for HIV Product and Services
Table 55. Janssen Pharmaceuticals, Inc. Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 56. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 57. AbbVie Inc. Drugs for HIV Major Business
Table 58. AbbVie Inc. Drugs for HIV Total Revenue (USD Million) (2018-2019)
Table 59. AbbVie Inc. SWOT Analysis
Table 60. AbbVie Inc. Drugs for HIV Product and Services
Table 61. AbbVie Inc. Drugs for HIV Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 62. Global Drugs for HIV Sales by Manufacturer (2018-2019) (K Units)
Table 63. Global Drugs for HIV Revenue by Manufacturer (2018-2019) (USD Million)
Table 64. Global Drugs for HIV Sales by Regions (2015-2020) (K Units)
Table 65. Global Drugs for HIV Sales Market Share by Regions (2015-2020)
Table 66. Global Drugs for HIV Revenue by Regions (2015-2020) (USD Million)
Table 67. North America Drugs for HIV Sales by Countries (2015-2020) (K Units)
Table 68. North America Drugs for HIV Sales Market Share by Countries (2015-2020)
Table 69. North America Drugs for HIV Revenue by Countries (2015-2020) (USD Million)
Table 70. North America Drugs for HIV Revenue Market Share by Countries (2015-2020)
Table 71. Europe Drugs for HIV Sales by Countries (2015-2020) (K Units)
Table 72. Europe Drugs for HIV Sales Market Share by Countries (2015-2020)
Table 73. Europe Drugs for HIV Revenue by Countries (2015-2020) (USD Million)
Table 74. Asia-Pacific Drugs for HIV Sales by Regions (2015-2020) (K Units)
Table 75. Asia-Pacific Drugs for HIV Sales Market Share by Regions (2015-2020)
Table 76. Asia-Pacific Drugs for HIV Revenue by Regions (2015-2020) (USD Million)
Table 77. South America Drugs for HIV Sales by Countries (2015-2020) (K Units)
Table 78. South America Drugs for HIV Sales Market Share by Countries (2015-2020)
Table 79. South America Drugs for HIV Revenue by Countries (2015-2020) (USD Million)
Table 80. South America Drugs for HIV Revenue Market Share by Countries (2015-2020)
Table 81. Middle East & Africa Drugs for HIV Sales by Countries (2015-2020) (K Units)
Table 82. Middle East & Africa Drugs for HIV Sales Market Share by Countries (2015-2020)
Table 83. Middle East & Africa Drugs for HIV Revenue by Countries (2015-2020) (USD Million)
Table 84. Middle East & Africa Drugs for HIV Revenue Market Share by Countries (2015-2020)
Table 85. Global Drugs for HIV Sales by Type (2015-2020) (K Units)
Table 86. Global Drugs for HIV Sales Share by Type (2015-2020)
Table 87. Global Drugs for HIV Revenue by Type (2015-2020) (USD Million)
Table 88. Global Drugs for HIV Revenue Share by Type (2015-2020)
Table 89. Global Drugs for HIV Sales by Application (2015-2020) (K Units)
Table 90. Global Drugs for HIV Sales Share by Application (2015-2020)
Table 91. Global Drugs for HIV Sales Forecast by Regions (2021-2025) (K Units)
Table 92. Global Drugs for HIV Market Share Forecast by Regions (2021-2025)
Table 93. Global Drugs for HIV Sales Forecast by Type (2021-2025) (K Units)
Table 94. Global Drugs for HIV Market Share Forecast by Type (2021-2025)
Table 95. Global Drugs for HIV Sales Forecast by Application (2021-2025)
Table 96. Global Drugs for HIV Market Share Forecast by Application (2021-2025)
Table 97. Direct Channel Pros & Cons
Table 98. Indirect Channel Pros & Cons
Table 99. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Drugs for HIV Picture
Figure 2. Global Sales Market Share of Drugs for HIV by Type in 2019
Figure 3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Picture
Figure 4. Integrase Inhibitors Picture
Figure 5. Combination HIV Medicines Picture
Figure 6. Others Picture
Figure 7. Drugs for HIV Sales Market Share by Application in 2018
Figure 8. Hospital Pharmacies Picture
Figure 9. Retail Pharmacies Picture
Figure 10. Online Pharmacies Picture
Figure 11. Others Picture
Figure 12. Global Drugs for HIV Market Status and Outlook (2015-2025) (USD Million)
Figure 13. United States Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Canada Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Mexico Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Germany Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 17. France Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 18. UK Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Russia Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Italy Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 21. China Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Japan Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Korea Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 24. India Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Southeast Asia Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Australia Drugs for HIV Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 27. Brazil Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Egypt Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Saudi Arabia Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 30. South Africa Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Turkey Drugs for HIV Revenue (Value) and Growth Rate (2015-2025)
Figure 32. Global Drugs for HIV Sales Market Share by Manufacturer in 2019
Figure 33. Global Drugs for HIV Revenue Market Share by Manufacturer in 2019
Figure 34. Top 3 Drugs for HIV Manufacturer (Revenue) Market Share in 2019
Figure 35. Top 6 Drugs for HIV Manufacturer (Revenue) Market Share in 2019
Figure 36. Key Manufacturer Market Share Trend
Figure 37. Global Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 38. Global Drugs for HIV Revenue and Growth Rate (2015-2020) (USD Million)
Figure 39. Global Drugs for HIV Revenue Market Share by Regions (2015-2020)
Figure 40. Global Drugs for HIV Revenue Market Share by Regions in 2018
Figure 41. North America Drugs for HIV Sales and Growth Rate (2015-2020)
Figure 42. Europe Drugs for HIV Sales and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Drugs for HIV Sales and Growth Rate (2015-2020)
Figure 44. South America Drugs for HIV Sales and Growth Rate (2015-2020)
Figure 45. Middle East & Africa Drugs for HIV Sales and Growth Rate (2015-2020)
Figure 46. North America Drugs for HIV Revenue and Growth Rate (2015-2020) (USD Million)
Figure 47. North America Drugs for HIV Sales Market Share by Countries (2015-2020)
Figure 48. North America Drugs for HIV Sales Market Share by Countries in 2018
Figure 49. North America Drugs for HIV Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 50. North America Drugs for HIV Revenue Market Share by Countries in 2018
Figure 51. United States Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 52. Canada Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 53. Mexico Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 54. Europe Drugs for HIV Revenue and Growth Rate (2015-2020) (USD Million)
Figure 55. Europe Drugs for HIV Revenue Market Share by Countries (2015-2020)
Figure 56. Europe Drugs for HIV Revenue Market Share by Countries in 2019
Figure 57. Germany Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 58. UK Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 59. France Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 60. Russia Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 61. Italy Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 62. Asia-Pacific Drugs for HIV Revenue and Growth Rate (2015-2020) (USD Million)
Figure 63. Asia-Pacific Drugs for HIV Sales Market Share by Regions 2019
Figure 64. Asia-Pacific Drugs for HIV Revenue Market Share by Regions 2019
Figure 65. China Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 66. Japan Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 67. Korea Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 68. India Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 69. Southeast Asia Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 70. South America Drugs for HIV Revenue and Growth Rate (2015-2020) (USD Million)
Figure 71. South America Drugs for HIV Sales Market Share by Countries in 2019
Figure 72. South America Drugs for HIV Revenue Market Share by Countries in 2019
Figure 73. Brazil Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 74. Argentina Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 75. Middle East and Africa Drugs for HIV Revenue and Growth Rate (2015-2020) (USD Million)
Figure 76. Middle East and Africa Drugs for HIV Sales Market Share by Countries in 2019
Figure 77. Middle East and Africa Drugs for HIV Revenue Market Share by Countries (2015-2020)
Figure 78. Middle East and Africa Drugs for HIV Revenue Market Share by Countries in 2019
Figure 79. Saudi Arabia Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 80. Egypt Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 81. Turkey Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 82. South Africa Drugs for HIV Sales and Growth Rate (2015-2020) (K Units)
Figure 83. Global Drugs for HIV Sales and Growth Rate (2021-2025) (K Units)
Figure 84. Global Drugs for HIV Revenue and Growth Rate (2021-2025) (USD Million)
Figure 85. North America Sales Drugs for HIV Market Forecast (2021-2025) (K Units)
Figure 86. Europe Sales Drugs for HIV Market Forecast (2021-2025) (K Units)
Figure 87. Asia-Pacific Sales Drugs for HIV Market Forecast (2021-2025) (K Units)
Figure 88. South America Sales Drugs for HIV Market Forecast (2021-2025) (K Units)
Figure 89. Middle East & Africa Sales Drugs for HIV Market Forecast (2021-2025) (K Units)
Figure 90. Sales Channel: Direct Channel vs Indirect Channel
バーター症候群薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Bartter Syndrome Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Bartter Syndrome Drugs…- β-ラクタム系抗生剤の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Beta-Lactam Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tra…
- 抗マイコバクテリア薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Antimycobacterial Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Antimycobacterial Dru…
- OTC外用薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global OTC Topical Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The OTC Topical Drugs market re…
- ドライアイ治療薬・デバイス治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Dry Eye Drugs and Devices Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Dry Eye D…